Loading...
Clinicians often combine a tricyclic antidepressant and an SSRI to treat depressed patients who do not respond to either one alone. In a 6-week, double-blind trial, 39 patients with unipolar nonpsychotic depression that was refractory to at least 4 weeks of an adequate dose of one antidepressant were randomized to receive the norepinephrine reuptake inhibitor and tricyclic antidepressant desipramine (target plasma level, 160 ng/mL), the SSRI fluoxetine (dosage, 20 mg/day), or a combination of fluoxetine (20 mg/day) and desipramine (combination-treatment patients had higher desipramine levels than monotherapy patients because of the metabolic effects of fluoxetine). The blinding was maintained by using placebo fluoxetine or desipramine in th…